Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study
Identifieur interne : 002E95 ( Pmc/Checkpoint ); précédent : 002E94; suivant : 002E96Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study
Auteurs : N F Khan [Royaume-Uni] ; D. Mant [Royaume-Uni] ; L. Carpenter [Royaume-Uni] ; D. Forman [France] ; P W Rose [Royaume-Uni]Source :
- British Journal of Cancer [ 0007-0920 ] ; 2011.
Abstract
The community-based incidence of cancer treatment-related long-term consequences is uncertain. We sought to establish the burden of health outcomes that have been associated with treatment among British long-term cancer survivors.
We identified 26 213 adults from the General Practice Research Database who have survived 5 years or more following breast, colorectal or prostate cancer. Four age-, sex- and general practice-matched non-cancer controls were selected for each survivor. We considered the incidence of treatment-associated health outcomes using Cox proportional hazards models.
Breast cancer survivors had an elevated incidence of heart failure (hazards ratio (HR) 1.95, 95% confidence interval (CI) 1.27–3.01), coronary artery disease (HR 1.27, 95% CI 1.11–1.44), hypothyroidism (HR 1.26, 95% CI 1.02–1.56) and osteoporosis (HR 1.26, 95% CI 1.13–1.40). Among colorectal cancer survivors, there was increased incidence of dementia (HR 1.68, 95% CI 1.20–2.35), diabetes (HR 1.39, 95% CI 1.12–1.72) and osteoporosis (HR 1.41, 95% CI 1.15–1.73). Prostate cancer survivors had the highest risk of osteoporosis (HR 2.49, 95% CI 1.93–3.22).
The study confirms the occurrence of increased incidence of chronic illnesses in long-term cancer survivors attributable to underlying lifestyle and/or cancer treatments. Although the absolute risk of the majority of late effects in the cancer survivors cohort is low, identifying prior risk of osteoporosis by bone mineral density scanning for prostate survivors should be considered. There is an urgent need to improve primary care recording of cancer treatment.
Url:
DOI: 10.1038/bjc.2011.420
PubMed: 22048030
PubMed Central: 3251947
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
PMC:3251947Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study</title><author><name sortKey="Khan, N F" sort="Khan, N F" uniqKey="Khan N" first="N F" last="Khan">N F Khan</name><affiliation wicri:level="1"><nlm:aff id="aff1"><institution>Department of Primary Care Health Sciences, University of Oxford</institution>, 2nd Floor, 23-38 Hythe Bridge Street, Oxford OX1 2ET,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Mant, D" sort="Mant, D" uniqKey="Mant D" first="D" last="Mant">D. Mant</name><affiliation wicri:level="1"><nlm:aff id="aff1"><institution>Department of Primary Care Health Sciences, University of Oxford</institution>, 2nd Floor, 23-38 Hythe Bridge Street, Oxford OX1 2ET,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Carpenter, L" sort="Carpenter, L" uniqKey="Carpenter L" first="L" last="Carpenter">L. Carpenter</name><affiliation wicri:level="1"><nlm:aff id="aff2"><institution>Department of Public Health, University of Oxford</institution>, Rosemary Rue Building, Old Road Campus, Oxford OX3 7LF,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Forman, D" sort="Forman, D" uniqKey="Forman D" first="D" last="Forman">D. Forman</name><affiliation wicri:level="1"><nlm:aff id="aff3"><institution>Cancer Information Section, International Agency for Research on Cancer</institution>, 150, Cours Albert Thomas, F-69372 Lyon Cedex 08,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Rose, P W" sort="Rose, P W" uniqKey="Rose P" first="P W" last="Rose">P W Rose</name><affiliation wicri:level="1"><nlm:aff id="aff1"><institution>Department of Primary Care Health Sciences, University of Oxford</institution>, 2nd Floor, 23-38 Hythe Bridge Street, Oxford OX1 2ET,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">22048030</idno><idno type="pmc">3251947</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251947</idno><idno type="RBID">PMC:3251947</idno><idno type="doi">10.1038/bjc.2011.420</idno><date when="2011">2011</date><idno type="wicri:Area/Pmc/Corpus">000072</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000072</idno><idno type="wicri:Area/Pmc/Curation">000072</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000072</idno><idno type="wicri:Area/Pmc/Checkpoint">002E95</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002E95</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study</title><author><name sortKey="Khan, N F" sort="Khan, N F" uniqKey="Khan N" first="N F" last="Khan">N F Khan</name><affiliation wicri:level="1"><nlm:aff id="aff1"><institution>Department of Primary Care Health Sciences, University of Oxford</institution>, 2nd Floor, 23-38 Hythe Bridge Street, Oxford OX1 2ET,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Mant, D" sort="Mant, D" uniqKey="Mant D" first="D" last="Mant">D. Mant</name><affiliation wicri:level="1"><nlm:aff id="aff1"><institution>Department of Primary Care Health Sciences, University of Oxford</institution>, 2nd Floor, 23-38 Hythe Bridge Street, Oxford OX1 2ET,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Carpenter, L" sort="Carpenter, L" uniqKey="Carpenter L" first="L" last="Carpenter">L. Carpenter</name><affiliation wicri:level="1"><nlm:aff id="aff2"><institution>Department of Public Health, University of Oxford</institution>, Rosemary Rue Building, Old Road Campus, Oxford OX3 7LF,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Forman, D" sort="Forman, D" uniqKey="Forman D" first="D" last="Forman">D. Forman</name><affiliation wicri:level="1"><nlm:aff id="aff3"><institution>Cancer Information Section, International Agency for Research on Cancer</institution>, 150, Cours Albert Thomas, F-69372 Lyon Cedex 08,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Rose, P W" sort="Rose, P W" uniqKey="Rose P" first="P W" last="Rose">P W Rose</name><affiliation wicri:level="1"><nlm:aff id="aff1"><institution>Department of Primary Care Health Sciences, University of Oxford</institution>, 2nd Floor, 23-38 Hythe Bridge Street, Oxford OX1 2ET,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author></analytic><series><title level="j">British Journal of Cancer</title><idno type="ISSN">0007-0920</idno><idno type="eISSN">1532-1827</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Background:</title><p>The community-based incidence of cancer treatment-related long-term consequences is uncertain. We sought to establish the burden of health outcomes that have been associated with treatment among British long-term cancer survivors.</p></sec><sec><title>Methods:</title><p>We identified 26 213 adults from the General Practice Research Database who have survived 5 years or more following breast, colorectal or prostate cancer. Four age-, sex- and general practice-matched non-cancer controls were selected for each survivor. We considered the incidence of treatment-associated health outcomes using Cox proportional hazards models.</p></sec><sec><title>Results:</title><p>Breast cancer survivors had an elevated incidence of heart failure (hazards ratio (HR) 1.95, 95% confidence interval (CI) 1.27–3.01), coronary artery disease (HR 1.27, 95% CI 1.11–1.44), hypothyroidism (HR 1.26, 95% CI 1.02–1.56) and osteoporosis (HR 1.26, 95% CI 1.13–1.40). Among colorectal cancer survivors, there was increased incidence of dementia (HR 1.68, 95% CI 1.20–2.35), diabetes (HR 1.39, 95% CI 1.12–1.72) and osteoporosis (HR 1.41, 95% CI 1.15–1.73). Prostate cancer survivors had the highest risk of osteoporosis (HR 2.49, 95% CI 1.93–3.22).</p></sec><sec><title>Conclusions:</title><p>The study confirms the occurrence of increased incidence of chronic illnesses in long-term cancer survivors attributable to underlying lifestyle and/or cancer treatments. Although the absolute risk of the majority of late effects in the cancer survivors cohort is low, identifying prior risk of osteoporosis by bone mineral density scanning for prostate survivors should be considered. There is an urgent need to improve primary care recording of cancer treatment.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Bianchini, F" uniqKey="Bianchini F">F Bianchini</name></author><author><name sortKey="Vainio, H" uniqKey="Vainio H">H Vainio</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bradbury, Bd" uniqKey="Bradbury B">BD Bradbury</name></author><author><name sortKey="Lash, Tl" uniqKey="Lash T">TL Lash</name></author><author><name sortKey="Kaye, Ja" uniqKey="Kaye J">JA Kaye</name></author><author><name sortKey="Jick, Ss" uniqKey="Jick S">SS Jick</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brown, Je" uniqKey="Brown J">JE Brown</name></author><author><name sortKey="Sherriff, Jm" uniqKey="Sherriff J">JM Sherriff</name></author><author><name sortKey="James, Nd" uniqKey="James N">ND James</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Carver, Jr" uniqKey="Carver J">JR Carver</name></author><author><name sortKey="Shapiro, Cl" uniqKey="Shapiro C">CL Shapiro</name></author><author><name sortKey="Ng, A" uniqKey="Ng A">A Ng</name></author><author><name sortKey="Jacobs, L" uniqKey="Jacobs L">L Jacobs</name></author><author><name sortKey="Schwartz, C" uniqKey="Schwartz C">C Schwartz</name></author><author><name sortKey="Virgo, Ks" uniqKey="Virgo K">KS Virgo</name></author><author><name sortKey="Hagerty, Kl" uniqKey="Hagerty K">KL Hagerty</name></author><author><name sortKey="Somerfield, Mr" uniqKey="Somerfield M">MR Somerfield</name></author><author><name sortKey="Vaughn, Dj" uniqKey="Vaughn D">DJ Vaughn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Charlson, Me" uniqKey="Charlson M">ME Charlson</name></author><author><name sortKey="Pompei, P" uniqKey="Pompei P">P Pompei</name></author><author><name sortKey="Ales, Kl" uniqKey="Ales K">KL Ales</name></author><author><name sortKey="Mackenzie, Cr" uniqKey="Mackenzie C">CR MacKenzie</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, Rc" uniqKey="Chen R">RC Chen</name></author><author><name sortKey="Clark, Ja" uniqKey="Clark J">JA Clark</name></author><author><name sortKey="Talcott, Ja" uniqKey="Talcott J">JA Talcott</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, Z" uniqKey="Chen Z">Z Chen</name></author><author><name sortKey="Maricic, M" uniqKey="Maricic M">M Maricic</name></author><author><name sortKey="Pettinger, M" uniqKey="Pettinger M">M Pettinger</name></author><author><name sortKey="Ritenbaugh, C" uniqKey="Ritenbaugh C">C Ritenbaugh</name></author><author><name sortKey="Lopez, Am" uniqKey="Lopez A">AM Lopez</name></author><author><name sortKey="Barad, Dh" uniqKey="Barad D">DH Barad</name></author><author><name sortKey="Gass, M" uniqKey="Gass M">M Gass</name></author><author><name sortKey="Leboff, Ms" uniqKey="Leboff M">MS Leboff</name></author><author><name sortKey="Bassford, Tl" uniqKey="Bassford T">TL Bassford</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Choueiri, Tk" uniqKey="Choueiri T">TK Choueiri</name></author><author><name sortKey="Mayer, El" uniqKey="Mayer E">EL Mayer</name></author><author><name sortKey="Je, Y" uniqKey="Je Y">Y Je</name></author><author><name sortKey="Rosenberg, Je" uniqKey="Rosenberg J">JE Rosenberg</name></author><author><name sortKey="Nguyen, Pl" uniqKey="Nguyen P">PL Nguyen</name></author><author><name sortKey="Azzi, Gr" uniqKey="Azzi G">GR Azzi</name></author><author><name sortKey="Bellmunt, J" uniqKey="Bellmunt J">J Bellmunt</name></author><author><name sortKey="Burstein, Hj" uniqKey="Burstein H">HJ Burstein</name></author><author><name sortKey="Schutz, Fa" uniqKey="Schutz F">FA Schutz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Clarke, M" uniqKey="Clarke M">M Clarke</name></author><author><name sortKey="Collins, R" uniqKey="Collins R">R Collins</name></author><author><name sortKey="Darby, S" uniqKey="Darby S">S Darby</name></author><author><name sortKey="Davies, C" uniqKey="Davies C">C Davies</name></author><author><name sortKey="Elphinstone, P" uniqKey="Elphinstone P">P Elphinstone</name></author><author><name sortKey="Evans, E" uniqKey="Evans E">E Evans</name></author><author><name sortKey="Godwin, J" uniqKey="Godwin J">J Godwin</name></author><author><name sortKey="Gray, R" uniqKey="Gray R">R Gray</name></author><author><name sortKey="Hicks, C" uniqKey="Hicks C">C Hicks</name></author><author><name sortKey="James, S" uniqKey="James S">S James</name></author><author><name sortKey="Mackinnon, E" uniqKey="Mackinnon E">E MacKinnon</name></author><author><name sortKey="Mcgale, P" uniqKey="Mcgale P">P McGale</name></author><author><name sortKey="Mchugh, T" uniqKey="Mchugh T">T McHugh</name></author><author><name sortKey="Peto, R" uniqKey="Peto R">R Peto</name></author><author><name sortKey="Taylor, C" uniqKey="Taylor C">C Taylor</name></author><author><name sortKey="Wang, Y" uniqKey="Wang Y">Y Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cleves, Ma" uniqKey="Cleves M">MA Cleves</name></author><author><name sortKey="Gould, Wg" uniqKey="Gould W">WG Gould</name></author><author><name sortKey="Gutierrez, R" uniqKey="Gutierrez R">R Gutierrez</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Darby, Sc" uniqKey="Darby S">SC Darby</name></author><author><name sortKey="Mcgale, P" uniqKey="Mcgale P">P McGale</name></author><author><name sortKey="Taylor, Cw" uniqKey="Taylor C">CW Taylor</name></author><author><name sortKey="Peto, R" uniqKey="Peto R">R Peto</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Farnell, Dj" uniqKey="Farnell D">DJ Farnell</name></author><author><name sortKey="Mandall, P" uniqKey="Mandall P">P Mandall</name></author><author><name sortKey="Anandadas, C" uniqKey="Anandadas C">C Anandadas</name></author><author><name sortKey="Routledge, J" uniqKey="Routledge J">J Routledge</name></author><author><name sortKey="Burns, Mp" uniqKey="Burns M">MP Burns</name></author><author><name sortKey="Logue, Jp" uniqKey="Logue J">JP Logue</name></author><author><name sortKey="Wylie, Jp" uniqKey="Wylie J">JP Wylie</name></author><author><name sortKey="Swindell, R" uniqKey="Swindell R">R Swindell</name></author><author><name sortKey="Livsey, J" uniqKey="Livsey J">J Livsey</name></author><author><name sortKey="West, Cm" uniqKey="West C">CM West</name></author><author><name sortKey="Davidson, Se" uniqKey="Davidson S">SE Davidson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hansell, A" uniqKey="Hansell A">A Hansell</name></author><author><name sortKey="Hollowell, J" uniqKey="Hollowell J">J Hollowell</name></author><author><name sortKey="Nichols, T" uniqKey="Nichols T">T Nichols</name></author><author><name sortKey="Mcniece, R" uniqKey="Mcniece R">R McNiece</name></author><author><name sortKey="Strachan, D" uniqKey="Strachan D">D Strachan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Heflin, Lh" uniqKey="Heflin L">LH Heflin</name></author><author><name sortKey="Meyerowitz, Be" uniqKey="Meyerowitz B">BE Meyerowitz</name></author><author><name sortKey="Hall, P" uniqKey="Hall P">P Hall</name></author><author><name sortKey="Lichtenstein, P" uniqKey="Lichtenstein P">P Lichtenstein</name></author><author><name sortKey="Johansson, B" uniqKey="Johansson B">B Johansson</name></author><author><name sortKey="Pedersen, Nl" uniqKey="Pedersen N">NL Pedersen</name></author><author><name sortKey="Gatz, M" uniqKey="Gatz M">M Gatz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Henson, Cc" uniqKey="Henson C">CC Henson</name></author><author><name sortKey="Andreyev, Hj" uniqKey="Andreyev H">HJ Andreyev</name></author><author><name sortKey="Symonds, Rp" uniqKey="Symonds R">RP Symonds</name></author><author><name sortKey="Peel, D" uniqKey="Peel D">D Peel</name></author><author><name sortKey="Swindell, R" uniqKey="Swindell R">R Swindell</name></author><author><name sortKey="Davidson, Se" uniqKey="Davidson S">SE Davidson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hewitt, M" uniqKey="Hewitt M">M Hewitt</name></author><author><name sortKey="Greenfield, S" uniqKey="Greenfield S">S Greenfield</name></author><author><name sortKey="Stovall, E" uniqKey="Stovall E">E Stovall</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kanis, Ja" uniqKey="Kanis J">JA Kanis</name></author><author><name sortKey="Johnell, O" uniqKey="Johnell O">O Johnell</name></author><author><name sortKey="Oden, A" uniqKey="Oden A">A Oden</name></author><author><name sortKey="Johansson, H" uniqKey="Johansson H">H Johansson</name></author><author><name sortKey="De, Lc" uniqKey="De L">LC De</name></author><author><name sortKey="Eisman, Ja" uniqKey="Eisman J">JA Eisman</name></author><author><name sortKey="Fujiwara, S" uniqKey="Fujiwara S">S Fujiwara</name></author><author><name sortKey="Kroger, H" uniqKey="Kroger H">H Kroger</name></author><author><name sortKey="Mccloskey, Ev" uniqKey="Mccloskey E">EV McCloskey</name></author><author><name sortKey="Mellstrom, D" uniqKey="Mellstrom D">D Mellstrom</name></author><author><name sortKey="Melton, Lj" uniqKey="Melton L">LJ Melton</name></author><author><name sortKey="Pols, H" uniqKey="Pols H">H Pols</name></author><author><name sortKey="Reeve, J" uniqKey="Reeve J">J Reeve</name></author><author><name sortKey="Silman, A" uniqKey="Silman A">A Silman</name></author><author><name sortKey="Tenenhouse, A" uniqKey="Tenenhouse A">A Tenenhouse</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Keating, Nl" uniqKey="Keating N">NL Keating</name></author><author><name sortKey="O Malley, Aj" uniqKey="O Malley A">AJ O'Malley</name></author><author><name sortKey="Smith, Mr" uniqKey="Smith M">MR Smith</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Keefe, Dl" uniqKey="Keefe D">DL Keefe</name></author><author><name sortKey="Roistacher, N" uniqKey="Roistacher N">N Roistacher</name></author><author><name sortKey="Pierri, Mk" uniqKey="Pierri M">MK Pierri</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Khan, Nf" uniqKey="Khan N">NF Khan</name></author><author><name sortKey="Harrison, Se" uniqKey="Harrison S">SE Harrison</name></author><author><name sortKey="Rose, Pw" uniqKey="Rose P">PW Rose</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Khan, Nf" uniqKey="Khan N">NF Khan</name></author><author><name sortKey="Perera, R" uniqKey="Perera R">R Perera</name></author><author><name sortKey="Harper, S" uniqKey="Harper S">S Harper</name></author><author><name sortKey="Rose, Pw" uniqKey="Rose P">PW Rose</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Larsson, Sc" uniqKey="Larsson S">SC Larsson</name></author><author><name sortKey="Orsini, N" uniqKey="Orsini N">N Orsini</name></author><author><name sortKey="Wolk, A" uniqKey="Wolk A">A Wolk</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lewis, Jd" uniqKey="Lewis J">JD Lewis</name></author><author><name sortKey="Brensinger, C" uniqKey="Brensinger C">C Brensinger</name></author><author><name sortKey="Lewis, Jd" uniqKey="Lewis J">JD Lewis</name></author><author><name sortKey="Brensinger, C" uniqKey="Brensinger C">C Brensinger</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lopez, Am" uniqKey="Lopez A">AM Lopez</name></author><author><name sortKey="Pena, Ma" uniqKey="Pena M">MA Pena</name></author><author><name sortKey="Hernandez, R" uniqKey="Hernandez R">R Hernandez</name></author><author><name sortKey="Val, F" uniqKey="Val F">F Val</name></author><author><name sortKey="Martin, B" uniqKey="Martin B">B Martin</name></author><author><name sortKey="Riancho, Ja" uniqKey="Riancho J">JA Riancho</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Mincey, Ba" uniqKey="Mincey B">BA Mincey</name></author><author><name sortKey="Duh, Ms" uniqKey="Duh M">MS Duh</name></author><author><name sortKey="Thomas, Sk" uniqKey="Thomas S">SK Thomas</name></author><author><name sortKey="Moyneur, E" uniqKey="Moyneur E">E Moyneur</name></author><author><name sortKey="Marynchencko, M" uniqKey="Marynchencko M">M Marynchencko</name></author><author><name sortKey="Boyce, Sp" uniqKey="Boyce S">SP Boyce</name></author><author><name sortKey="Mallett, D" uniqKey="Mallett D">D Mallett</name></author><author><name sortKey="Perez, Ea" uniqKey="Perez E">EA Perez</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Oeffinger, Kc" uniqKey="Oeffinger K">KC Oeffinger</name></author><author><name sortKey="Mertens, Ac" uniqKey="Mertens A">AC Mertens</name></author><author><name sortKey="Sklar, Ca" uniqKey="Sklar C">CA Sklar</name></author><author><name sortKey="Kawashima, T" uniqKey="Kawashima T">T Kawashima</name></author><author><name sortKey="Hudson, Mm" uniqKey="Hudson M">MM Hudson</name></author><author><name sortKey="Meadows, At" uniqKey="Meadows A">AT Meadows</name></author><author><name sortKey="Friedman, Dl" uniqKey="Friedman D">DL Friedman</name></author><author><name sortKey="Marina, N" uniqKey="Marina N">N Marina</name></author><author><name sortKey="Hobbie, W" uniqKey="Hobbie W">W Hobbie</name></author><author><name sortKey="Kadan Lottic, Ns" uniqKey="Kadan Lottic N">NS Kadan-Lottic</name></author><author><name sortKey="Schwartz, Cl" uniqKey="Schwartz C">CL Schwartz</name></author><author><name sortKey="Leisenring, W" uniqKey="Leisenring W">W Leisenring</name></author><author><name sortKey="Robison, Ll" uniqKey="Robison L">LL Robison</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Partridge, Ah" uniqKey="Partridge A">AH Partridge</name></author><author><name sortKey="Burstein, Hj" uniqKey="Burstein H">HJ Burstein</name></author><author><name sortKey="Winer, Ep" uniqKey="Winer E">EP Winer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Paskett, Ed" uniqKey="Paskett E">ED Paskett</name></author><author><name sortKey="Stark, N" uniqKey="Stark N">N Stark</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pinder, Mc" uniqKey="Pinder M">MC Pinder</name></author><author><name sortKey="Duan, Z" uniqKey="Duan Z">Z Duan</name></author><author><name sortKey="Goodwin, Js" uniqKey="Goodwin J">JS Goodwin</name></author><author><name sortKey="Hortobagyi, Gn" uniqKey="Hortobagyi G">GN Hortobagyi</name></author><author><name sortKey="Giordano, Sh" uniqKey="Giordano S">SH Giordano</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Reulen, Rc" uniqKey="Reulen R">RC Reulen</name></author><author><name sortKey="Winter, Dl" uniqKey="Winter D">DL Winter</name></author><author><name sortKey="Lancashire, Er" uniqKey="Lancashire E">ER Lancashire</name></author><author><name sortKey="Zeegers, Mp" uniqKey="Zeegers M">MP Zeegers</name></author><author><name sortKey="Jenney, Me" uniqKey="Jenney M">ME Jenney</name></author><author><name sortKey="Walters, Sj" uniqKey="Walters S">SJ Walters</name></author><author><name sortKey="Jenkinson, C" uniqKey="Jenkinson C">C Jenkinson</name></author><author><name sortKey="Hawkins, Mm" uniqKey="Hawkins M">MM Hawkins</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Saad, F" uniqKey="Saad F">F Saad</name></author><author><name sortKey="Adachi, Jd" uniqKey="Adachi J">JD Adachi</name></author><author><name sortKey="Brown, Jp" uniqKey="Brown J">JP Brown</name></author><author><name sortKey="Canning, La" uniqKey="Canning L">LA Canning</name></author><author><name sortKey="Gelmon, Ka" uniqKey="Gelmon K">KA Gelmon</name></author><author><name sortKey="Josse, Rg" uniqKey="Josse R">RG Josse</name></author><author><name sortKey="Pritchard, Ki" uniqKey="Pritchard K">KI Pritchard</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Saigal, Cs" uniqKey="Saigal C">CS Saigal</name></author><author><name sortKey="Gore, Jl" uniqKey="Gore J">JL Gore</name></author><author><name sortKey="Krupski, Tl" uniqKey="Krupski T">TL Krupski</name></author><author><name sortKey="Hanley, J" uniqKey="Hanley J">J Hanley</name></author><author><name sortKey="Schonlau, M" uniqKey="Schonlau M">M Schonlau</name></author><author><name sortKey="Litwin, Ms" uniqKey="Litwin M">MS Litwin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schover, Lr" uniqKey="Schover L">LR Schover</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Senkus, E" uniqKey="Senkus E">E Senkus</name></author><author><name sortKey="Jassem, J" uniqKey="Jassem J">J Jassem</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shahinian, Vb" uniqKey="Shahinian V">VB Shahinian</name></author><author><name sortKey="Kuo, Yf" uniqKey="Kuo Y">YF Kuo</name></author><author><name sortKey="Freeman, Jl" uniqKey="Freeman J">JL Freeman</name></author><author><name sortKey="Goodwin, Js" uniqKey="Goodwin J">JS Goodwin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Smith, Gl" uniqKey="Smith G">GL Smith</name></author><author><name sortKey="Smith, Bd" uniqKey="Smith B">BD Smith</name></author><author><name sortKey="Giordano, Sh" uniqKey="Giordano S">SH Giordano</name></author><author><name sortKey="Shih, Yc" uniqKey="Shih Y">YC Shih</name></author><author><name sortKey="Woodward, Wa" uniqKey="Woodward W">WA Woodward</name></author><author><name sortKey="Strom, Ea" uniqKey="Strom E">EA Strom</name></author><author><name sortKey="Perkins, Gh" uniqKey="Perkins G">GH Perkins</name></author><author><name sortKey="Tereffe, W" uniqKey="Tereffe W">W Tereffe</name></author><author><name sortKey="Yu, Tk" uniqKey="Yu T">TK Yu</name></author><author><name sortKey="Buchholz, Ta" uniqKey="Buchholz T">TA Buchholz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Taylor, Lg" uniqKey="Taylor L">LG Taylor</name></author><author><name sortKey="Canfield, Se" uniqKey="Canfield S">SE Canfield</name></author><author><name sortKey="Du, Xl" uniqKey="Du X">XL Du</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Walley, T" uniqKey="Walley T">T Walley</name></author><author><name sortKey="Mantgani, A" uniqKey="Mantgani A">A Mantgani</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wefel, Js" uniqKey="Wefel J">JS Wefel</name></author><author><name sortKey="Meyers, Ca" uniqKey="Meyers C">CA Meyers</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22048030</article-id><article-id pub-id-type="pmc">3251947</article-id><article-id pub-id-type="pii">bjc2011420</article-id><article-id pub-id-type="doi">10.1038/bjc.2011.420</article-id><article-categories><subj-group subj-group-type="heading"><subject>Full Paper</subject></subj-group></article-categories><title-group><article-title>Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study</article-title><alt-title alt-title-type="running">Late effects in cancer survivors</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Khan</surname><given-names>N F</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Mant</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Carpenter</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Forman</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Rose</surname><given-names>P W</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><aff id="aff1"><label>1</label><institution>Department of Primary Care Health Sciences, University of Oxford</institution>, 2nd Floor, 23-38 Hythe Bridge Street, Oxford OX1 2ET,<country>UK</country></aff><aff id="aff2"><label>2</label><institution>Department of Public Health, University of Oxford</institution>, Rosemary Rue Building, Old Road Campus, Oxford OX3 7LF,<country>UK</country></aff><aff id="aff3"><label>3</label><institution>Cancer Information Section, International Agency for Research on Cancer</institution>, 150, Cours Albert Thomas, F-69372 Lyon Cedex 08,<country>France</country></aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>E-mail: <email>nada.khan@phc.ox.ac.uk</email></corresp></author-notes><pub-date pub-type="ppub"><day>08</day><month>11</month><year>2011</year></pub-date><pub-date pub-type="epub"><day>03</day><month>11</month><year>2011</year></pub-date><pub-date pub-type="pmc-release"><day>8</day><month>11</month><year>2011</year></pub-date><volume>105</volume><issue>Suppl 1</issue><fpage>S29</fpage><lpage>S37</lpage><permissions><copyright-statement>Copyright © 2011 Cancer Research UK</copyright-statement><copyright-year>2011</copyright-year><copyright-holder>Cancer Research UK</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0/"><pmc-comment>author-paid</pmc-comment>
<license-p>This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/</license-p></license></permissions><abstract><sec><title>Background:</title><p>The community-based incidence of cancer treatment-related long-term consequences is uncertain. We sought to establish the burden of health outcomes that have been associated with treatment among British long-term cancer survivors.</p></sec><sec><title>Methods:</title><p>We identified 26 213 adults from the General Practice Research Database who have survived 5 years or more following breast, colorectal or prostate cancer. Four age-, sex- and general practice-matched non-cancer controls were selected for each survivor. We considered the incidence of treatment-associated health outcomes using Cox proportional hazards models.</p></sec><sec><title>Results:</title><p>Breast cancer survivors had an elevated incidence of heart failure (hazards ratio (HR) 1.95, 95% confidence interval (CI) 1.27–3.01), coronary artery disease (HR 1.27, 95% CI 1.11–1.44), hypothyroidism (HR 1.26, 95% CI 1.02–1.56) and osteoporosis (HR 1.26, 95% CI 1.13–1.40). Among colorectal cancer survivors, there was increased incidence of dementia (HR 1.68, 95% CI 1.20–2.35), diabetes (HR 1.39, 95% CI 1.12–1.72) and osteoporosis (HR 1.41, 95% CI 1.15–1.73). Prostate cancer survivors had the highest risk of osteoporosis (HR 2.49, 95% CI 1.93–3.22).</p></sec><sec><title>Conclusions:</title><p>The study confirms the occurrence of increased incidence of chronic illnesses in long-term cancer survivors attributable to underlying lifestyle and/or cancer treatments. Although the absolute risk of the majority of late effects in the cancer survivors cohort is low, identifying prior risk of osteoporosis by bone mineral density scanning for prostate survivors should be considered. There is an urgent need to improve primary care recording of cancer treatment.</p></sec></abstract><kwd-group><kwd>neoplasms</kwd><kwd>primary health care</kwd><kwd>survivors</kwd><kwd>comorbidity</kwd><kwd>long-term care</kwd></kwd-group></article-meta></front><floats-group><table-wrap id="tbl1"><label>Table 1</label><caption><title>Examples of potential long-term and late effects of treatment amongst breast, colorectal and prostate cancer survivors</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="left"></col><col align="left"></col><col align="left"></col><col align="left"></col><col align="left"></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Surgery</bold></th><th align="left" valign="top" charoff="50"><bold>Radiotherapy</bold></th><th colspan="2" align="center" valign="top" charoff="50"><bold>Chemotherapy</bold></th><th colspan="2" align="center" valign="top" charoff="50"><bold>Hormone therapy</bold></th></tr></thead><tbody valign="top"><tr><td colspan="6" align="left" valign="top" charoff="50"><italic>Breast</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Lymphoedema</td><td align="left" valign="top" charoff="50">Shoulder stiffening
Lymphoedema
Hypothyroidism
Skin telangiectasia</td><td align="left" valign="top" charoff="50">Anthracyclines</td><td align="left" valign="top" charoff="50">Heart failure
Left ventricular (LV) dysfunction (<xref ref-type="bibr" rid="bib17">Hewitt <italic>et al</italic>, 2006</xref>)</td><td align="left" valign="top" charoff="50">Tamoxifen</td><td align="left" valign="top" charoff="50">Endometrial cancer
Osteopenia
Thromboembolic events (<xref ref-type="bibr" rid="bib17">Hewitt <italic>et al</italic>, 2006</xref>)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">Cardiac damage
Second malignancy
Thyroid damage</td><td align="left" valign="top" charoff="50">Cyclophosphamide</td><td align="left" valign="top" charoff="50">Heart failure
Pericarditis
Premature menopause (<xref ref-type="bibr" rid="bib17">Hewitt <italic>et al</italic>, 2006</xref>)</td><td align="left" valign="top" charoff="50">Aromatase inhibitors</td><td align="left" valign="top" charoff="50">Bone loss (<xref ref-type="bibr" rid="bib27">Mincey <italic>et al</italic>, 2006</xref>)
Possible increased risk of artherosclerosis (<xref ref-type="bibr" rid="bib38">Senkus and Jassem, 2011</xref>)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">Trastuzumab</td><td align="left" valign="top" charoff="50">Heart failure
LV dysfunction (<xref ref-type="bibr" rid="bib17">Hewitt <italic>et al</italic>, 2006</xref>)</td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">Bevacizumab</td><td align="left" valign="top" charoff="50">Hypertension
Thromoembolic events
Heart failure (<xref ref-type="bibr" rid="bib9">Choueiri <italic>et al</italic>, 2011</xref>)</td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">General effects</td><td align="left" valign="top" charoff="50">Weight gain
Cognitive dysfunction (<xref ref-type="bibr" rid="bib31">Partridge <italic>et al</italic>, 2001</xref>)</td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td colspan="6" align="left" valign="top" charoff="50"><italic>Prostate</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Urinary incontinence
Sexual dysfunction</td><td align="left" valign="top" charoff="50">Pelvic fibrosis
Bowel fibrosis
Bladder/bowel telangiectasia</td><td align="left" valign="top" charoff="50">Rarely used</td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">LHRH analogues</td><td align="left" valign="top" charoff="50">Coronary artery disease (<xref ref-type="bibr" rid="bib36">Saigal <italic>et al</italic>, 2007</xref>)
Myocardial infarction (<xref ref-type="bibr" rid="bib41">Taylor <italic>et al</italic>, 2009</xref>)
Osteoporosis (<xref ref-type="bibr" rid="bib25">Lopez <italic>et al</italic>, 2005</xref>; <xref ref-type="bibr" rid="bib41">Taylor <italic>et al</italic>, 2009</xref>)
Mild obesity (<xref ref-type="bibr" rid="bib17">Hewitt <italic>et al</italic>, 2006</xref>)
Sexual dysfunction (<xref ref-type="bibr" rid="bib37">Schover, 2005</xref>)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">Bicalutamide</td><td align="left" valign="top" charoff="50">Breast enlargement (<xref ref-type="bibr" rid="bib17">Hewitt <italic>et al</italic>, 2006</xref>)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td colspan="6" align="left" valign="top" charoff="50"><italic>Colorectal</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Stoma
Bowel and urinary incontinence
Sexual dysfunction</td><td align="left" valign="top" charoff="50">Pelvic necrosis
Hip osteoporosis</td><td align="left" valign="top" charoff="50">Bevacizumab</td><td align="left" valign="top" charoff="50">Hypertension
Thromoembolic events
Heart failure (<xref ref-type="bibr" rid="bib17">Hewitt <italic>et al</italic>, 2006</xref>)</td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">5-Fluorouracil</td><td align="left" valign="top" charoff="50">Cardiac ischaemia (<xref ref-type="bibr" rid="bib20">Keefe <italic>et al</italic>, 1993</xref>)</td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">Oxaliplatin</td><td align="left" valign="top" charoff="50">Peripheral neuropathy (<xref ref-type="bibr" rid="bib17">Hewitt <italic>et al</italic>, 2006</xref>)</td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50">General effects</td><td align="left" valign="top" charoff="50">Cognitive dysfunction (<xref ref-type="bibr" rid="bib15">Heflin <italic>et al</italic>, 2005</xref>)</td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr></tbody></table><table-wrap-foot><fn id="t1-fn1"><p>Abbreviation: LHRH=lutenizing hormone-releasing hormone.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2"><label>Table 2</label><caption><title>Characteristics of cancer survivors and matched controls (four patients of the same age and gender from the same primary care practice without a diagnosis of cancer) by cancer type</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"> </th><th colspan="2" align="center" valign="top" charoff="50"><bold>Breast</bold><hr></hr></th><th colspan="2" align="center" valign="top" charoff="50"><bold>Colorectal</bold><hr></hr></th><th colspan="2" align="center" valign="top" charoff="50"><bold>Prostate</bold><hr></hr></th></tr><tr><th align="left" valign="top" charoff="50"> </th><th align="center" valign="top" charoff="50"><bold>Survivor</bold></th><th align="center" valign="top" charoff="50"><bold>Control</bold></th><th align="center" valign="top" charoff="50"><bold>Survivor</bold></th><th align="center" valign="top" charoff="50"><bold>Control</bold></th><th align="center" valign="top" charoff="50"><bold>Survivor</bold></th><th align="center" valign="top" charoff="50"><bold>Control</bold></th></tr></thead><tbody valign="top"><tr><td colspan="7" align="left" valign="top" charoff="50"><italic>Gender</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Male</td><td align="center" valign="top" charoff="50">—</td><td align="center" valign="top" charoff="50">—</td><td align="center" valign="top" charoff="50">2569</td><td align="center" valign="top" charoff="50">10 178</td><td align="center" valign="top" charoff="50">4207</td><td align="center" valign="top" charoff="50">16 709</td></tr><tr><td align="left" valign="top" charoff="50"> Female</td><td align="center" valign="top" charoff="50">16 938</td><td align="center" valign="top" charoff="50">67 649</td><td align="center" valign="top" charoff="50">2499</td><td align="center" valign="top" charoff="50">9950</td><td align="center" valign="top" charoff="50">—</td><td align="center" valign="top" charoff="50">—</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"><italic>Mean age</italic><xref ref-type="fn" rid="t2-fn1">a</xref> (<italic>in years</italic>)</td><td colspan="2" align="center" valign="top" charoff="50">66.9</td><td colspan="2" align="center" valign="top" charoff="50">74.1</td><td colspan="2" align="center" valign="top" charoff="50">76.1</td></tr><tr><td align="left" valign="top" charoff="50"> Standard deviation</td><td colspan="2" align="center" valign="top" charoff="50">12.3</td><td colspan="2" align="center" valign="top" charoff="50">10.9</td><td colspan="2" align="center" valign="top" charoff="50">8.1</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"><italic>Mean years from diagnosis</italic><xref ref-type="fn" rid="t2-fn1">a</xref></td><td align="center" valign="top" charoff="50">10.2</td><td align="center" valign="top" charoff="50">—</td><td align="center" valign="top" charoff="50">10.1</td><td align="center" valign="top" charoff="50">—</td><td align="center" valign="top" charoff="50">5.8</td><td align="center" valign="top" charoff="50">—</td></tr><tr><td align="left" valign="top" charoff="50"> Standard deviation</td><td align="center" valign="top" charoff="50">7.5</td><td align="center" valign="top" charoff="50">—</td><td align="center" valign="top" charoff="50">7.9</td><td align="center" valign="top" charoff="50">—</td><td align="center" valign="top" charoff="50">3.6</td><td align="center" valign="top" charoff="50">—</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"><italic>Charlson comorbidity score>0</italic></td><td align="center" valign="top" charoff="50">7551</td><td align="center" valign="top" charoff="50">27 999</td><td align="center" valign="top" charoff="50">2942</td><td align="center" valign="top" charoff="50">10 343</td><td align="center" valign="top" charoff="50">2693</td><td align="center" valign="top" charoff="50">9345</td></tr><tr><td align="left" valign="top" charoff="50"> %</td><td align="center" valign="top" charoff="50">44.6%</td><td align="center" valign="top" charoff="50">41.4%</td><td align="center" valign="top" charoff="50">58.1%</td><td align="center" valign="top" charoff="50">51.4%</td><td align="center" valign="top" charoff="50">64.0%</td><td align="center" valign="top" charoff="50">55.9%</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td colspan="7" align="left" valign="top" charoff="50"><italic>Smoking status</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Ever smoked</td><td align="center" valign="top" charoff="50">5738</td><td align="center" valign="top" charoff="50">23 188</td><td align="center" valign="top" charoff="50">2238</td><td align="center" valign="top" charoff="50">8428</td><td align="center" valign="top" charoff="50">2139</td><td align="center" valign="top" charoff="50">9012</td></tr><tr><td align="left" valign="top" charoff="50"> %</td><td align="center" valign="top" charoff="50">33.9%</td><td align="center" valign="top" charoff="50">34.3%</td><td align="center" valign="top" charoff="50">44.1%</td><td align="center" valign="top" charoff="50">41.9%</td><td align="center" valign="top" charoff="50">50.8%</td><td align="center" valign="top" charoff="50">53.9%</td></tr><tr><td align="left" valign="top" charoff="50"> Never smoked</td><td align="center" valign="top" charoff="50">10 703</td><td align="center" valign="top" charoff="50">42 452</td><td align="center" valign="top" charoff="50">2662</td><td align="center" valign="top" charoff="50">10 889</td><td align="center" valign="top" charoff="50">1968</td><td align="center" valign="top" charoff="50">7044</td></tr><tr><td align="left" valign="top" charoff="50"> %</td><td align="center" valign="top" charoff="50">63.2%</td><td align="center" valign="top" charoff="50">62.8%</td><td align="center" valign="top" charoff="50">52.5%</td><td align="center" valign="top" charoff="50">54.1%</td><td align="center" valign="top" charoff="50">46.8%</td><td align="center" valign="top" charoff="50">42.2%</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td colspan="7" align="left" valign="top" charoff="50"><italic>BMI</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Underweight</td><td align="center" valign="top" charoff="50">583</td><td align="center" valign="top" charoff="50">2264</td><td align="center" valign="top" charoff="50">160</td><td align="center" valign="top" charoff="50">616</td><td align="center" valign="top" charoff="50">77</td><td align="center" valign="top" charoff="50">359</td></tr><tr><td align="left" valign="top" charoff="50"> %</td><td align="center" valign="top" charoff="50">3.9%</td><td align="center" valign="top" charoff="50">3.8%</td><td align="center" valign="top" charoff="50">3.7%</td><td align="center" valign="top" charoff="50">3.6%</td><td align="center" valign="top" charoff="50">2.1%</td><td align="center" valign="top" charoff="50">2.5%</td></tr><tr><td align="left" valign="top" charoff="50"> Normal weight</td><td align="center" valign="top" charoff="50">6046</td><td align="center" valign="top" charoff="50">23 651</td><td align="center" valign="top" charoff="50">1618</td><td align="center" valign="top" charoff="50">6654</td><td align="center" valign="top" charoff="50">1380</td><td align="center" valign="top" charoff="50">5651</td></tr><tr><td align="left" valign="top" charoff="50"> %</td><td align="center" valign="top" charoff="50">41.2%</td><td align="center" valign="top" charoff="50">39.8%</td><td align="center" valign="top" charoff="50">37.8%</td><td align="center" valign="top" charoff="50">38.9%</td><td align="center" valign="top" charoff="50">37.3%</td><td align="center" valign="top" charoff="50">39.1%</td></tr><tr><td align="left" valign="top" charoff="50"> Overweight</td><td align="center" valign="top" charoff="50">5030</td><td align="center" valign="top" charoff="50">20 169</td><td align="center" valign="top" charoff="50">1695</td><td align="center" valign="top" charoff="50">6781</td><td align="center" valign="top" charoff="50">1625</td><td align="center" valign="top" charoff="50">6355</td></tr><tr><td align="left" valign="top" charoff="50"> %</td><td align="center" valign="top" charoff="50">34.3%</td><td align="center" valign="top" charoff="50">33.9%</td><td align="center" valign="top" charoff="50">39.6%</td><td align="center" valign="top" charoff="50">39.7%</td><td align="center" valign="top" charoff="50">43.9%</td><td align="center" valign="top" charoff="50">43.9%</td></tr><tr><td align="left" valign="top" charoff="50"> Obese</td><td align="center" valign="top" charoff="50">3023</td><td align="center" valign="top" charoff="50">13 296</td><td align="center" valign="top" charoff="50">804</td><td align="center" valign="top" charoff="50">3033</td><td align="center" valign="top" charoff="50">623</td><td align="center" valign="top" charoff="50">2105</td></tr><tr><td align="left" valign="top" charoff="50"> %</td><td align="center" valign="top" charoff="50">20.6%</td><td align="center" valign="top" charoff="50">22.4%</td><td align="center" valign="top" charoff="50">18.8%</td><td align="center" valign="top" charoff="50">17.8%</td><td align="center" valign="top" charoff="50">16.8%</td><td align="center" valign="top" charoff="50">14.6%</td></tr></tbody></table><table-wrap-foot><fn id="t2-fn1"><label>a</label><p>The date used to calculate years from cancer diagnosis was 1 September 2003, and the year used to calculate age was 2003.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl3"><label>Table 3</label><caption><title>Incidence of new diagnoses related to treatment amongst breast cancer survivors</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="char" char="."></col><col align="char" char="."></col><col align="left"></col><col align="char" char="."></col><col align="left"></col><col align="char" char="."></col><col align="left"></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"> </th><th colspan="3" align="center" valign="top" char="." charoff="50"><bold>Incidence</bold><hr></hr></th><th colspan="4" align="center" valign="top" char="." charoff="50"><bold>Hazard ratio<xref ref-type="fn" rid="t3-fn2">a</xref></bold><hr></hr></th></tr><tr><th align="left" valign="top" charoff="50"> </th><th align="char" valign="top" char="." charoff="50"><bold><italic>n</italic></bold></th><th align="char" valign="top" char="." charoff="50"><bold>Incidence rate per 1000 person-years</bold></th><th align="left" valign="top" charoff="50"><bold>95% CI</bold></th><th align="char" valign="top" char="." charoff="50"><bold>Unadjusted</bold></th><th align="left" valign="top" charoff="50"><bold>95% CI</bold></th><th align="char" valign="top" char="." charoff="50"><bold>Adjusted</bold></th><th align="left" valign="top" charoff="50"><bold>95% CI</bold></th></tr></thead><tbody valign="top"><tr><td colspan="8" align="left" valign="top" charoff="50"><italic>Heart failure</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Cancer survivors</td><td align="char" valign="top" char="." charoff="50">228</td><td align="char" valign="top" char="." charoff="50">5.73</td><td align="left" valign="top" charoff="50">5.0–6.5</td><td align="char" valign="top" char="." charoff="50">1.80</td><td align="left" valign="top" charoff="50">1.51–2.13</td><td align="char" valign="top" char="." charoff="50">1.95</td><td align="left" valign="top" charoff="50">1.27–3.01</td></tr><tr><td align="left" valign="top" charoff="50"> Controls without cancer</td><td align="char" valign="top" char="." charoff="50">760</td><td align="char" valign="top" char="." charoff="50">4.40</td><td align="left" valign="top" charoff="50">4.1–4.7</td><td align="char" valign="top" char="." charoff="50">—</td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td colspan="8" align="left" valign="top" charoff="50"><italic>Coronary artery disease</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Cancer survivors</td><td align="char" valign="top" char="." charoff="50">410</td><td align="char" valign="top" char="." charoff="50">10.86</td><td align="left" valign="top" charoff="50">9.9–12.0</td><td align="char" valign="top" char="." charoff="50">1.29</td><td align="left" valign="top" charoff="50">1.14–1.45</td><td align="char" valign="top" char="." charoff="50">1.27</td><td align="left" valign="top" charoff="50">1.11–1.44</td></tr><tr><td align="left" valign="top" charoff="50"> Controls without cancer</td><td align="char" valign="top" char="." charoff="50">1726</td><td align="char" valign="top" char="." charoff="50">10.60</td><td align="left" valign="top" charoff="50">10.1–11.1</td><td align="char" valign="top" char="." charoff="50">—</td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td colspan="8" align="left" valign="top" charoff="50"><italic>Dementia</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Cancer survivors</td><td align="char" valign="top" char="." charoff="50">211</td><td align="char" valign="top" char="." charoff="50">5.19</td><td align="left" valign="top" charoff="50">4.54–5.94</td><td align="char" valign="top" char="." charoff="50">1.62</td><td align="left" valign="top" charoff="50">1.36–1.93</td><td align="char" valign="top" char="." charoff="50">1.21</td><td align="left" valign="top" charoff="50">0.95–1.53</td></tr><tr><td align="left" valign="top" charoff="50"> Controls without cancer</td><td align="char" valign="top" char="." charoff="50">800</td><td align="char" valign="top" char="." charoff="50">4.52</td><td align="left" valign="top" charoff="50">4.22–4.85</td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td colspan="8" align="left" valign="top" charoff="50"><italic>Hypothyroidism</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Cancer survivors</td><td align="char" valign="top" char="." charoff="50">437</td><td align="char" valign="top" char="." charoff="50">11.76</td><td align="left" valign="top" charoff="50">10.7–12.9</td><td align="char" valign="top" char="." charoff="50">1.18</td><td align="left" valign="top" charoff="50">1.05–1.32</td><td align="char" valign="top" char="." charoff="50">1.26</td><td align="left" valign="top" charoff="50">1.02–1.56</td></tr><tr><td align="left" valign="top" charoff="50"> Controls without cancer</td><td align="char" valign="top" char="." charoff="50">1772</td><td align="char" valign="top" char="." charoff="50">10.95</td><td align="left" valign="top" charoff="50">10.5–11.5</td><td align="char" valign="top" char="." charoff="50">—</td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td colspan="8" align="left" valign="top" charoff="50"><italic>Osteoporosis</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Cancer survivors</td><td align="char" valign="top" char="." charoff="50">656</td><td align="char" valign="top" char="." charoff="50">18.07</td><td align="left" valign="top" charoff="50">16.7–19.5</td><td align="char" valign="top" char="." charoff="50">1.40</td><td align="left" valign="top" charoff="50">1.28–1.54</td><td align="char" valign="top" char="." charoff="50">1.26</td><td align="left" valign="top" charoff="50">1.13–1.40</td></tr><tr><td align="left" valign="top" charoff="50"> Controls without cancer</td><td align="char" valign="top" char="." charoff="50">2305</td><td align="char" valign="top" char="." charoff="50">14.57</td><td align="left" valign="top" charoff="50">13.9–15.2</td><td align="char" valign="top" char="." charoff="50">—</td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td colspan="8" align="left" valign="top" charoff="50"><italic>Lymphoedema</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Cancer survivors</td><td align="char" valign="top" char="." charoff="50">260</td><td align="char" valign="top" char="." charoff="50">6.73</td><td align="left" valign="top" charoff="50">5.95–7.59</td><td align="char" valign="top" char="." charoff="50">18.12</td><td align="left" valign="top" charoff="50">13.6–24.1</td><td align="char" valign="top" char="." charoff="50">—</td><td align="left" valign="top" charoff="50">—</td></tr><tr><td align="left" valign="top" charoff="50"> Controls without cancer</td><td align="char" valign="top" char="." charoff="50">77</td><td align="char" valign="top" char="." charoff="50">0.34</td><td align="left" valign="top" charoff="50">0.34–0.54</td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td colspan="8" align="left" valign="top" charoff="50"><italic>Early menopause</italic><xref ref-type="fn" rid="t3-fn3">b</xref></td></tr><tr><td align="left" valign="top" charoff="50"> Cancer survivors</td><td align="char" valign="top" char="." charoff="50">186</td><td align="char" valign="top" char="." charoff="50">4.51</td><td align="left" valign="top" charoff="50">3.91–5.21</td><td align="char" valign="top" char="." charoff="50">1.25</td><td align="left" valign="top" charoff="50">1.06–1.48</td><td align="char" valign="top" char="." charoff="50">1.25</td><td align="left" valign="top" charoff="50">1.06–1.48</td></tr><tr><td align="left" valign="top" charoff="50"> Controls without cancer</td><td align="char" valign="top" char="." charoff="50">664</td><td align="char" valign="top" char="." charoff="50">3.72</td><td align="left" valign="top" charoff="50">3.45–4.02</td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr></tbody></table><table-wrap-foot><fn id="t3-fn1"><p>Abbreviation: CI=confidence interval.</p></fn><fn id="t3-fn2"><label>a</label><p>The hazard ratio in each case is based on individual comparison with controls matched for age, gender and primary care practice (i.e., the comparison for patients treated with radiotherapy is with controls individually matched to patients receiving radiotherapy rather than all controls); the adjusted hazard ratio takes account of the potential confounding effect of smoking and BMI (except for hypothyroidism which is adjusted for BMI and history of hormone therapy only, and early menopause which is adjusted for smoking only).</p></fn><fn id="t3-fn3"><label>b</label><p>Defined as menopause before the age of 48 years.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl4"><label>Table 4</label><caption><title>Incidence of new diagnoses related to treatment among colorectal cancer survivors</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="char" char="."></col><col align="char" char="."></col><col align="left"></col><col align="char" char="."></col><col align="left"></col><col align="char" char="."></col><col align="left"></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"> </th><th colspan="3" align="center" valign="top" char="." charoff="50"><bold>Incidence</bold><hr></hr></th><th colspan="4" align="center" valign="top" char="." charoff="50"><bold>Hazard ratio<xref ref-type="fn" rid="t4-fn2">a</xref></bold><hr></hr></th></tr><tr><th align="left" valign="top" charoff="50"> </th><th align="char" valign="top" char="." charoff="50"><bold><italic>n</italic></bold></th><th align="char" valign="top" char="." charoff="50"><bold>Incidence rate per 1000 person-years</bold></th><th align="left" valign="top" charoff="50"><bold>95% CI</bold></th><th align="char" valign="top" char="." charoff="50"><bold>Unadjusted</bold></th><th align="left" valign="top" charoff="50"><bold>95% CI</bold></th><th align="char" valign="top" char="." charoff="50"><bold>Adjusted</bold></th><th align="left" valign="top" charoff="50"><bold>95% CI</bold></th></tr></thead><tbody valign="top"><tr><td colspan="8" align="left" valign="top" charoff="50"><italic>Dementia</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Cancer survivors</td><td align="char" valign="top" char="." charoff="50">116</td><td align="char" valign="top" char="." charoff="50">10.08</td><td align="left" valign="top" charoff="50">8.4–12.1</td><td align="char" valign="top" char="." charoff="50">2.10</td><td align="left" valign="top" charoff="50">1.65–2.68</td><td align="char" valign="top" char="." charoff="50">1.68</td><td align="left" valign="top" charoff="50">1.20–2.35</td></tr><tr><td align="left" valign="top" charoff="50"> Controls without cancer</td><td align="char" valign="top" char="." charoff="50">356</td><td align="char" valign="top" char="." charoff="50">7.02</td><td align="left" valign="top" charoff="50">6.3–7.8</td><td align="char" valign="top" char="." charoff="50">—</td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td colspan="8" align="left" valign="top" charoff="50"><italic>Osteoporosis</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Cancer survivors</td><td align="char" valign="top" char="." charoff="50">190</td><td align="char" valign="top" char="." charoff="50">18.02</td><td align="left" valign="top" charoff="50">15.6–20.8</td><td align="char" valign="top" char="." charoff="50">1.60</td><td align="left" valign="top" charoff="50">1.35–1.91</td><td align="char" valign="top" char="." charoff="50">1.41</td><td align="left" valign="top" charoff="50">1.15–1.73</td></tr><tr><td align="left" valign="top" charoff="50"> Controls without cancer</td><td align="char" valign="top" char="." charoff="50">597</td><td align="char" valign="top" char="." charoff="50">12.86</td><td align="left" valign="top" charoff="50">11.9–13.9</td><td align="char" valign="top" char="." charoff="50">—</td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td colspan="8" align="left" valign="top" charoff="50"><italic>Diabetes</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Cancer survivors</td><td align="char" valign="top" char="." charoff="50">176</td><td align="char" valign="top" char="." charoff="50">17.01</td><td align="left" valign="top" charoff="50">14.7–19.7</td><td align="char" valign="top" char="." charoff="50">1.40</td><td align="left" valign="top" charoff="50">1.15–1.70</td><td align="char" valign="top" char="." charoff="50">1.39</td><td align="left" valign="top" charoff="50">1.12–1.72</td></tr><tr><td align="left" valign="top" charoff="50"> Controls without cancer</td><td align="char" valign="top" char="." charoff="50">616</td><td align="char" valign="top" char="." charoff="50">13.21</td><td align="left" valign="top" charoff="50">12.2–14.3</td><td align="char" valign="top" char="." charoff="50">—</td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td colspan="8" align="left" valign="top" charoff="50"><italic>Erectile dysfunction</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Cancer survivors</td><td align="char" valign="top" char="." charoff="50">118</td><td align="char" valign="top" char="." charoff="50">23.00</td><td align="left" valign="top" charoff="50">19.2–27.5</td><td align="char" valign="top" char="." charoff="50">1.42</td><td align="left" valign="top" charoff="50">1.11–1.81</td><td align="char" valign="top" char="." charoff="50">1.39</td><td align="left" valign="top" charoff="50">1.08–1.77</td></tr><tr><td align="left" valign="top" charoff="50"> Controls without cancer</td><td align="char" valign="top" char="." charoff="50">392</td><td align="char" valign="top" char="." charoff="50">16.55</td><td align="left" valign="top" charoff="50">14.9–18.3</td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td colspan="8" align="left" valign="top" charoff="50"><italic>Urinary incontinence</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Cancer survivors</td><td align="char" valign="top" char="." charoff="50">252</td><td align="char" valign="top" char="." charoff="50">14.49</td><td align="left" valign="top" charoff="50">12.8–16.4</td><td align="char" valign="top" char="." charoff="50">1.79</td><td align="left" valign="top" charoff="50">1.40–2.30</td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> Controls without cancer</td><td align="char" valign="top" char="." charoff="50">853</td><td align="char" valign="top" char="." charoff="50">12.09</td><td align="left" valign="top" charoff="50">11.3–12.9</td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td colspan="8" align="left" valign="top" charoff="50"><italic>Diarrhoea or constipation</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Cancer survivors</td><td align="char" valign="top" char="." charoff="50">441</td><td align="char" valign="top" char="." charoff="50">67.99</td><td align="left" valign="top" charoff="50">61.9–74.6</td><td align="char" valign="top" char="." charoff="50">1.43</td><td align="left" valign="top" charoff="50">1.26–1.63</td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> Controls without cancer</td><td align="char" valign="top" char="." charoff="50">1939</td><td align="char" valign="top" char="." charoff="50">51.68</td><td align="left" valign="top" charoff="50">49.4–54.0</td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr></tbody></table><table-wrap-foot><fn id="t4-fn1"><p>Abbreviation: CI=confidence interval.</p></fn><fn id="t4-fn2"><label>a</label><p>The hazard ratio in each case is based on individual comparison with controls matched for age, gender and primary care practice; the adjusted hazard ratio takes account of the potential confounding effect of comorbidity, BMI (and for osteoporosis and erectile dysfunction also for smoking).</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl5"><label>Table 5</label><caption><title>Incidence of new diagnoses related to treatment amongst prostate cancer survivors</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="char" char="."></col><col align="char" char="."></col><col align="left"></col><col align="char" char="."></col><col align="left"></col><col align="char" char="."></col><col align="left"></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"> </th><th colspan="3" align="center" valign="top" char="." charoff="50"><bold>Incidence</bold><hr></hr></th><th colspan="4" align="center" valign="top" char="." charoff="50"><bold>Hazard ratio<xref ref-type="fn" rid="t5-fn2">a</xref></bold><hr></hr></th></tr><tr><th align="left" valign="top" charoff="50"> </th><th align="char" valign="top" char="." charoff="50"><bold><italic>n</italic></bold></th><th align="char" valign="top" char="." charoff="50"><bold>Incidence rate per 1000 person-years</bold></th><th align="left" valign="top" charoff="50"><bold>95% CI</bold></th><th align="char" valign="top" char="." charoff="50"><bold>Unadjusted</bold></th><th align="left" valign="top" charoff="50"><bold>95% CI</bold></th><th align="char" valign="top" char="." charoff="50"><bold>Adjusted</bold></th><th align="left" valign="top" charoff="50"><bold>95% CI</bold></th></tr></thead><tbody valign="top"><tr><td colspan="8" align="left" valign="top" charoff="50"><italic>Heart failure</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Cancer survivors</td><td align="char" valign="top" char="." charoff="50">129</td><td align="char" valign="top" char="." charoff="50">17.1</td><td align="left" valign="top" charoff="50">14.4–20.3</td><td align="char" valign="top" char="." charoff="50">1.66</td><td align="left" valign="top" charoff="50">1.32–2.10</td><td align="char" valign="top" char="." charoff="50">1.23</td><td align="left" valign="top" charoff="50">0.91–1.66</td></tr><tr><td align="left" valign="top" charoff="50"> Controls without cancer</td><td align="char" valign="top" char="." charoff="50">486</td><td align="char" valign="top" char="." charoff="50">13.8</td><td align="left" valign="top" charoff="50">12.6–15.1</td><td align="char" valign="top" char="." charoff="50">—</td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td colspan="8" align="left" valign="top" charoff="50"><italic>Coronary artery disease</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Cancer survivors</td><td align="char" valign="top" char="." charoff="50">173</td><td align="char" valign="top" char="." charoff="50">27.95</td><td align="left" valign="top" charoff="50">24.1–32.4</td><td align="char" valign="top" char="." charoff="50">1.27</td><td align="left" valign="top" charoff="50">1.05–1.56</td><td align="char" valign="top" char="." charoff="50">1.17</td><td align="left" valign="top" charoff="50">0.94–1.46</td></tr><tr><td align="left" valign="top" charoff="50"> Controls without cancer</td><td align="char" valign="top" char="." charoff="50">863</td><td align="char" valign="top" char="." charoff="50">29.15</td><td align="left" valign="top" charoff="50">27.3–31.2</td><td align="char" valign="top" char="." charoff="50">—</td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td colspan="8" align="left" valign="top" charoff="50"><italic>Osteoporosis</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Cancer survivors</td><td align="char" valign="top" char="." charoff="50">120</td><td align="char" valign="top" char="." charoff="50">15.38</td><td align="left" valign="top" charoff="50">12.9–18.4</td><td align="char" valign="top" char="." charoff="50">2.39</td><td align="left" valign="top" charoff="50">1.89–3.00</td><td align="char" valign="top" char="." charoff="50">2.49</td><td align="left" valign="top" charoff="50">1.93–3.22</td></tr><tr><td align="left" valign="top" charoff="50"> Controls without cancer</td><td align="char" valign="top" char="." charoff="50">292</td><td align="char" valign="top" char="." charoff="50">7.98</td><td align="left" valign="top" charoff="50">7.1–8.9</td><td align="char" valign="top" char="." charoff="50">—</td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td colspan="8" align="left" valign="top" charoff="50"><italic>Erectile dysfunction</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Cancer survivors</td><td align="char" valign="top" char="." charoff="50">163</td><td align="char" valign="top" char="." charoff="50">23.51</td><td align="left" valign="top" charoff="50">20.2–27.4</td><td align="char" valign="top" char="." charoff="50">1.22</td><td align="left" valign="top" charoff="50">0.96–1.55</td><td align="char" valign="top" char="." charoff="50">1.17</td><td align="left" valign="top" charoff="50">0.91–1.49</td></tr><tr><td align="left" valign="top" charoff="50"> Controls without cancer</td><td align="char" valign="top" char="." charoff="50">563</td><td align="char" valign="top" char="." charoff="50">16.13</td><td align="left" valign="top" charoff="50">14.8–17.5</td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td colspan="8" align="left" valign="top" charoff="50"><italic>Urinary incontinence</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Cancer survivors</td><td align="char" valign="top" char="." charoff="50">315</td><td align="char" valign="top" char="." charoff="50">20.43</td><td align="left" valign="top" charoff="50">18.3–22.8</td><td align="char" valign="top" char="." charoff="50">3.20</td><td align="left" valign="top" charoff="50">2.45–4.16</td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> Controls without cancer</td><td align="char" valign="top" char="." charoff="50">677</td><td align="char" valign="top" char="." charoff="50">12.45</td><td align="left" valign="top" charoff="50">11.5–13.4</td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr></tbody></table><table-wrap-foot><fn id="t5-fn1"><p>Abbreviation: CI=confidence interval.</p></fn><fn id="t5-fn2"><label>a</label><p>The hazard ratio in each case is based on individual comparison with controls matched for age, gender and primary care practice (i.e. the comparison for patients treated with radiotherapy is with controls individually matched to patients receiving radiotherapy rather than all controls); the adjusted hazard ratio takes account of the potential confounding effect of comorbidity, smoking and BMI.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl6"><label>Table 6</label><caption><title>Total prevalence of long-term effects in cancer survivors and controls</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="left"></col><col align="left"></col><col align="left"></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"> </th><th align="left" valign="top" charoff="50"><bold>Number of events</bold></th><th align="left" valign="top" charoff="50"><bold>No event</bold></th><th align="left" valign="top" charoff="50"><bold>Total patients</bold></th></tr></thead><tbody valign="top"><tr><td colspan="4" align="left" valign="top" charoff="50"><italic>Urinary incontinence</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Prostate</td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> Survivor</td><td align="char" valign="top" char="(" charoff="50">411 (9.8%)<xref ref-type="fn" rid="t6-fn1">a</xref></td><td align="char" valign="top" char="(" charoff="50">3796 (90.2%)</td><td align="char" valign="top" char="." charoff="50">4207</td></tr><tr><td align="left" valign="top" charoff="50"> Control</td><td align="char" valign="top" char="(" charoff="50">525 (3.1%)</td><td align="char" valign="top" char="(" charoff="50">16 184 (96.9%)</td><td align="char" valign="top" char="." charoff="50">16 709</td></tr><tr><td align="left" valign="top" charoff="50"> Colorectal</td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> Survivor</td><td align="char" valign="top" char="(" charoff="50">324 (6.4%)<xref ref-type="fn" rid="t6-fn1">a</xref></td><td align="char" valign="top" char="(" charoff="50">4744 (93.6%)</td><td align="char" valign="top" char="." charoff="50">5068</td></tr><tr><td align="left" valign="top" charoff="50"> Control</td><td align="char" valign="top" char="(" charoff="50">1022 (5.1%)</td><td align="char" valign="top" char="(" charoff="50">19 106 (94.9%)</td><td align="char" valign="top" char="." charoff="50">20 128</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td colspan="4" align="left" valign="top" charoff="50"><italic>Erectile dysfunction</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Prostate</td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> Survivor</td><td align="char" valign="top" char="(" charoff="50">662 (15.7%)<xref ref-type="fn" rid="t6-fn1">a</xref></td><td align="char" valign="top" char="(" charoff="50">3545 (84.3%)</td><td align="char" valign="top" char="." charoff="50">4207</td></tr><tr><td align="left" valign="top" charoff="50"> Control</td><td align="char" valign="top" char="(" charoff="50">1394 (8.3%)</td><td align="char" valign="top" char="(" charoff="50">15 315 (91.7%)</td><td align="char" valign="top" char="." charoff="50">16 709</td></tr><tr><td align="left" valign="top" charoff="50"> Colorectal (men only)</td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> Survivor</td><td align="char" valign="top" char="(" charoff="50">344 (13.4%)<xref ref-type="fn" rid="t6-fn1">a</xref></td><td align="char" valign="top" char="(" charoff="50">2225 (86.6%)</td><td align="char" valign="top" char="." charoff="50">2569</td></tr><tr><td align="left" valign="top" charoff="50"> Control</td><td align="char" valign="top" char="(" charoff="50">931 (9.2%)</td><td align="char" valign="top" char="(" charoff="50">9247 (90.8%)</td><td align="char" valign="top" char="." charoff="50">10 178</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td colspan="4" align="left" valign="top" charoff="50"><italic>Diarrhoea or constipation</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Colorectal</td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> Survivor</td><td align="char" valign="top" char="(" charoff="50">2300 (45.4%)<xref ref-type="fn" rid="t6-fn1">a</xref></td><td align="char" valign="top" char="(" charoff="50">2768 (54.6%)</td><td align="char" valign="top" char="." charoff="50">5068</td></tr><tr><td align="left" valign="top" charoff="50"> Control</td><td align="char" valign="top" char="(" charoff="50">5792 (28.8%)</td><td align="char" valign="top" char="(" charoff="50">14 336 (71.2%)</td><td align="char" valign="top" char="." charoff="50">20 128</td></tr></tbody></table><table-wrap-foot><fn id="t6-fn1"><label>a</label><p>Significant at <italic>P</italic> <0.0001 in Pearson's <italic>X</italic><sup>2</sup>-comparisons.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbla1"><label>Table A1</label><caption><title>Treatment data available in GPRD-NCIN-linked database</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="char" char="."></col><col align="char" char="."></col><col align="char" char="."></col><col align="char" char="."></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"> </th><th align="char" valign="top" char="." charoff="50"><bold>Yes</bold></th><th align="char" valign="top" char="." charoff="50"><bold>No</bold></th><th align="char" valign="top" char="." charoff="50"><bold>Total</bold></th><th align="char" valign="top" char="." charoff="50"><bold>% Of total patients</bold></th></tr></thead><tbody valign="top"><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Radiotherapy</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Breast</td><td align="char" valign="top" char="." charoff="50">4509</td><td align="char" valign="top" char="." charoff="50">2539</td><td align="char" valign="top" char="." charoff="50">7048</td><td align="char" valign="top" char="." charoff="50">41.6</td></tr><tr><td align="left" valign="top" charoff="50"> Colorectal</td><td align="char" valign="top" char="." charoff="50">322</td><td align="char" valign="top" char="." charoff="50">1111</td><td align="char" valign="top" char="." charoff="50">1433</td><td align="char" valign="top" char="." charoff="50">28.3</td></tr><tr><td align="left" valign="top" charoff="50"> Prostate</td><td align="char" valign="top" char="." charoff="50">717</td><td align="char" valign="top" char="." charoff="50">974</td><td align="char" valign="top" char="." charoff="50">1691</td><td align="char" valign="top" char="." charoff="50">40.2</td></tr><tr><td align="left" valign="top" charoff="50"> Total</td><td align="char" valign="top" char="." charoff="50">5548</td><td align="char" valign="top" char="." charoff="50">4624</td><td align="char" valign="top" char="." charoff="50">10 172</td><td align="char" valign="top" char="." charoff="50">38.8</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Chemotherapy</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Breast</td><td align="char" valign="top" char="." charoff="50">2677</td><td align="char" valign="top" char="." charoff="50">3352</td><td align="char" valign="top" char="." charoff="50">6029</td><td align="char" valign="top" char="." charoff="50">35.6</td></tr><tr><td align="left" valign="top" charoff="50"> Colorectal</td><td align="char" valign="top" char="." charoff="50">684</td><td align="char" valign="top" char="." charoff="50">1010</td><td align="char" valign="top" char="." charoff="50">1694</td><td align="char" valign="top" char="." charoff="50">33.4</td></tr><tr><td align="left" valign="top" charoff="50"> Prostate</td><td align="char" valign="top" char="." charoff="50">171</td><td align="char" valign="top" char="." charoff="50">1187</td><td align="char" valign="top" char="." charoff="50">1358</td><td align="char" valign="top" char="." charoff="50">32.3</td></tr><tr><td align="left" valign="top" charoff="50"> Total</td><td align="char" valign="top" char="." charoff="50">3532</td><td align="char" valign="top" char="." charoff="50">5549</td><td align="char" valign="top" char="." charoff="50">9081</td><td align="char" valign="top" char="." charoff="50">34.6</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Surgery</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Breast</td><td align="char" valign="top" char="." charoff="50">4980</td><td align="char" valign="top" char="." charoff="50">1574</td><td align="char" valign="top" char="." charoff="50">6554</td><td align="char" valign="top" char="." charoff="50">38.7</td></tr><tr><td align="left" valign="top" charoff="50"> Colorectal</td><td align="char" valign="top" char="." charoff="50">1421</td><td align="char" valign="top" char="." charoff="50">501</td><td align="char" valign="top" char="." charoff="50">1922</td><td align="char" valign="top" char="." charoff="50">37.9</td></tr><tr><td align="left" valign="top" charoff="50"> Prostate</td><td align="char" valign="top" char="." charoff="50">1053</td><td align="char" valign="top" char="." charoff="50">812</td><td align="char" valign="top" char="." charoff="50">1865</td><td align="char" valign="top" char="." charoff="50">44.3</td></tr><tr><td align="left" valign="top" charoff="50"> Total</td><td align="char" valign="top" char="." charoff="50">7454</td><td align="char" valign="top" char="." charoff="50">2887</td><td align="char" valign="top" char="." charoff="50">10 341</td><td align="char" valign="top" char="." charoff="50">39.4</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Hormone therapy</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Breast</td><td align="char" valign="top" char="." charoff="50">13 304</td><td align="char" valign="top" char="." charoff="50">716</td><td align="char" valign="top" char="." charoff="50">14 020</td><td align="char" valign="top" char="." charoff="50">82.8</td></tr><tr><td align="left" valign="top" charoff="50"> Colorectal</td><td align="char" valign="top" char="." charoff="50">231</td><td align="char" valign="top" char="." charoff="50">1214</td><td align="char" valign="top" char="." charoff="50">1445</td><td align="char" valign="top" char="." charoff="50">28.5</td></tr><tr><td align="left" valign="top" charoff="50"> Prostate</td><td align="char" valign="top" char="." charoff="50">3197</td><td align="char" valign="top" char="." charoff="50">369</td><td align="char" valign="top" char="." charoff="50">3566</td><td align="char" valign="top" char="." charoff="50">84.8</td></tr><tr><td align="left" valign="top" charoff="50"> Total</td><td align="char" valign="top" char="." charoff="50">16 732</td><td align="char" valign="top" char="." charoff="50">2299</td><td align="char" valign="top" char="." charoff="50">19 031</td><td align="char" valign="top" char="." charoff="50">72.6</td></tr></tbody></table></table-wrap></floats-group></pmc><affiliations><list><country><li>France</li><li>Royaume-Uni</li></country></list><tree><country name="Royaume-Uni"><noRegion><name sortKey="Khan, N F" sort="Khan, N F" uniqKey="Khan N" first="N F" last="Khan">N F Khan</name></noRegion><name sortKey="Carpenter, L" sort="Carpenter, L" uniqKey="Carpenter L" first="L" last="Carpenter">L. Carpenter</name><name sortKey="Mant, D" sort="Mant, D" uniqKey="Mant D" first="D" last="Mant">D. Mant</name><name sortKey="Rose, P W" sort="Rose, P W" uniqKey="Rose P" first="P W" last="Rose">P W Rose</name></country><country name="France"><noRegion><name sortKey="Forman, D" sort="Forman, D" uniqKey="Forman D" first="D" last="Forman">D. Forman</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E95 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd -nk 002E95 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Pmc
|étape= Checkpoint
|type= RBID
|clé= PMC:3251947
|texte= Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/RBID.i -Sk "pubmed:22048030" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |